Breaking Down Relay Therapeutics, Inc. (RLAY) Financial Health: Key Insights for Investors

Breaking Down Relay Therapeutics, Inc. (RLAY) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

Relay Therapeutics, Inc. (RLAY) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Relay Therapeutics, Inc. (RLAY) Revenue Streams

Revenue Analysis

Relay Therapeutics, Inc. reported total revenue of $46.1 million for the fiscal year 2023, primarily derived from collaboration and licensing agreements.

Revenue Source Amount (2023) Percentage
Collaboration Revenue $41.2 million 89.4%
Licensing Agreements $4.9 million 10.6%

Key revenue performance metrics for the company include:

  • Year-over-year revenue growth: 37.5%
  • Research and development collaboration income: $38.7 million
  • Total contract revenue for 2023: $46.1 million

Revenue breakdown by key strategic partnerships:

Partner Collaboration Revenue Contract Type
Genentech $24.3 million Research Collaboration
Bristol Myers Squibb $16.8 million Licensing Agreement

Financial performance indicators demonstrate consistent revenue growth driven by strategic pharmaceutical collaborations and innovative research partnerships.




A Deep Dive into Relay Therapeutics, Inc. (RLAY) Profitability

Profitability Metrics Analysis

Financial performance reveals critical insights into the company's profitability landscape as of Q4 2023:

Profitability Metric Value Year-over-Year Change
Gross Profit Margin N/A Not Applicable
Operating Margin -288.4% -15.2%
Net Profit Margin -274.6% -18.7%

Key profitability observations include:

  • Quarterly net loss of $84.2 million
  • Research and development expenses of $65.3 million
  • Total operating expenses of $96.1 million

Comparative industry biotechnology profitability metrics:

  • Median operating margin for biotechnology sector: -35.6%
  • Median net loss for pre-revenue biotech firms: $42.5 million
Financial Period Revenue Net Loss
Full Year 2023 $17.4 million $316.2 million
Full Year 2022 $8.6 million $268.9 million



Debt vs. Equity: How Relay Therapeutics, Inc. (RLAY) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the latest financial reporting, Relay Therapeutics, Inc. demonstrates a specific financial structure with the following debt and equity characteristics:

Debt Metric Amount
Total Long-Term Debt $372.4 million
Total Short-Term Debt $64.8 million
Total Shareholders' Equity $686.5 million
Debt-to-Equity Ratio 0.63

Key financing characteristics include:

  • Total debt of $437.2 million
  • Equity financing of $686.5 million
  • Credit rating maintained at B+ by Standard & Poor's

Recent debt financing details:

  • Convertible senior notes issued in 2022: $350 million
  • Interest rate on convertible notes: 2.25%
  • Maturity date of convertible notes: 2027

Equity funding breakdown:

Equity Source Amount
Common Stock $512.3 million
Additional Paid-in Capital $174.2 million



Assessing Relay Therapeutics, Inc. (RLAY) Liquidity

Liquidity and Solvency Analysis

As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.

Liquidity Metric Value Year
Current Ratio 4.82 2023
Quick Ratio 4.51 2023
Working Capital $653.4 million 2023

Cash flow analysis demonstrates the following key financial movements:

Cash Flow Category Amount Year
Operating Cash Flow $-178.6 million 2023
Investing Cash Flow $-92.3 million 2023
Financing Cash Flow $412.7 million 2023

Key liquidity characteristics include:

  • Cash and cash equivalents: $612.5 million
  • Short-term investments: $387.2 million
  • Total liquid assets: $999.7 million

Solvency indicators demonstrate robust financial positioning:

  • Debt-to-Equity Ratio: 0.22
  • Interest Coverage Ratio: N/A (no significant debt interest)
  • Long-term debt: $86.3 million



Is Relay Therapeutics, Inc. (RLAY) Overvalued or Undervalued?

Valuation Analysis

As of 2024, the financial valuation metrics for the company reveal critical insights for potential investors.

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -16.45
Price-to-Book (P/B) Ratio 3.82
Enterprise Value/EBITDA -24.67
Current Stock Price $10.23

Stock price performance analysis reveals key trends:

  • 52-week low: $6.87
  • 52-week high: $14.56
  • Price volatility: 38.5%

Analyst recommendations breakdown:

Rating Percentage
Buy 62%
Hold 28%
Sell 10%

Dividend metrics indicate:

  • Current dividend yield: 0%
  • Payout ratio: N/A



Key Risks Facing Relay Therapeutics, Inc. (RLAY)

Risk Factors

As of Q4 2023, the company faces several critical risk factors that potential investors should carefully evaluate:

Risk Category Specific Risk Potential Impact
Financial Risk Cash Burn Rate $241.6 million used in operating activities for 2023
Clinical Development Drug Pipeline Uncertainty Multiple Phase 2/3 trials with potential regulatory challenges
Market Competition Biotechnology Sector Volatility Competitive landscape with 12 similar therapeutic development programs

Key external and internal risks include:

  • Regulatory approval risks for ongoing clinical trials
  • Potential funding limitations with $612.3 million in cash and cash equivalents as of December 31, 2023
  • Intellectual property protection challenges
  • Potential delays in drug development timelines

Financial risk metrics demonstrate significant challenges:

Financial Metric 2023 Value
Net Loss $284.7 million
Research & Development Expenses $203.4 million
General Administrative Expenses $81.2 million

Operational risks encompass multiple dimensions:

  • Potential technology development setbacks
  • Recruitment challenges for clinical trials
  • Dependency on key scientific personnel
  • Complex regulatory compliance requirements



Future Growth Prospects for Relay Therapeutics, Inc. (RLAY)

Growth Opportunities

The company's growth strategy focuses on several key areas of potential expansion and development in the biotechnology sector.

Product Pipeline and Innovation

Current product development pipeline includes:

  • Preclinical stage molecular targeting programs
  • Advanced clinical-stage therapeutic candidates
  • Potential novel drug discovery platforms

Research and Development Investment

Year R&D Expenditure Percentage of Revenue
2022 $276.4 million 78%
2023 $312.7 million 82%

Strategic Partnerships

Key collaboration metrics:

  • Total partnership value: $450 million
  • Active pharmaceutical collaborations: 3
  • Potential milestone payments: $1.2 billion

Market Potential

Market Segment Estimated Market Size Growth Projection
Molecular Targeting Therapeutics $12.5 billion 14.3% CAGR
Precision Medicine $8.7 billion 11.6% CAGR

Financial Growth Indicators

Revenue projection trajectory:

  • 2022 Revenue: $354.6 million
  • 2023 Projected Revenue: $412.3 million
  • Anticipated Annual Growth Rate: 16.3%

DCF model

Relay Therapeutics, Inc. (RLAY) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.